Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO(TM ... - MarketWatch (press release)

Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO(TM ... MarketWatch (press release) ELELYSO(TM) is a form of the human lysosomal enzyme, glucocerebrosidase, used to treat Gaucher disease. "The approval of ELELYSO is important for patients who depend on available ERT to manage their Gaucher disease. At Protalix, our passion to develop ... and more »

Halozyme Reports First Quarter 2012 Financial Results - MarketWatch (press release)

Halozyme Reports First Quarter 2012 Financial Results MarketWatch (press release) Notification from the European Patent Office (EPO) that a hearing scheduled in opposition of the European patent for Halozyme's recombinant human hyaluronidase enzyme (rHuPH20) was cancelled and the EPO acknowledged the patentability of the claims. and more »

Verenium Corporation's CEO Discusses Q1 2012 Results - Earnings Call Transcript - Seeking Alpha

Verenium Corporation's CEO Discusses Q1 2012 Results - Earnings Call Transcript Seeking Alpha First, you've heard us talk in the past about how our technology can create the highest-performing enzymes. Our sale of Purifine shows a global player like DSM clearly agreed with the substance of our claim. However, for our current portfolio, ... and more »

ZIOPHARM Oncology Appoints Jason A. Amello as Executive Vice President and ... - MarketWatch (press release)

ZIOPHARM Oncology Appoints Jason A. Amello as Executive Vice President and ... MarketWatch (press release) While at Genzyme, Mr. Amello served as one of the key executives in connection with the company's extensive mergers and acquisition and corporate partnering activities, which contributed to Genzyme's 5-fold growth over 10 years. and more »

Pfizer To Present New Data In Advanced Kidney, Lung And Hematologic Cancers At ... - FiercePharma

Pfizer To Present New Data In Advanced Kidney, Lung And Hematologic Cancers At ... FiercePharma Liver enzyme elevation has been observed during treatment with INLYTA. Monitor ALT, AST, and bilirubin before initiation of, and periodically throughout, treatment. For patients with moderate hepatic impairment, the starting dose should be decreased. and more »